search
Back to results

Impact of LOFT Therapy™ on Breast Cancer Survivors

Primary Purpose

Breast Neoplasms

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
LOFT Therapy
Sponsored by
Kathy Miller
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Breast Neoplasms focused on measuring Energy Expenditure, Physical Endurance, Muscle Stength, Metabolism

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed with stage 0-III breast cancer within the past 3 years
  • Must have completed local therapy for their breast cancer
  • Must have received systemic therapy for their breast cancer (anti-estrogen and/or chemotherapy)
  • Chemotherapy must be complete prior to entry
  • Anti-estrogen therapy may be ongoing
  • Ambulatory without assistive devices
  • No orthopedic restrictions or neurologic deficits that would limit ability to complete the Power Protocol (based on the opinion of the investigator)
  • No requirement for supplemental O2
  • No unstable angina, regular use of nitroglycerin for exertional angina, or MI within the last 12 months
  • No local or distant recurrence of their breast cancer
  • No active lymphedema
  • No history of hemorrhagic stroke
  • No Heparin or Coumadin Use
  • No symptomatic peripheral vascular obstructions
  • No active gallbladder disease
  • No active kidney stones
  • No active gout
  • No active diverticulitis
  • No pituitary diseases or growth
  • Able to provide written informed consent and authorization for release of health information
  • Able to commit to LOFT training 2 times/week for 4 weeks

Exclusion Criteria:

  • Inability to meet one of the inclusion criteria above.

Sites / Locations

  • Indiana University Health Hospital
  • Indiana University Melvin and Bren Simon Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

LOFT Therapy

Arm Description

LOFT therapy twice weekly for 4 weeks

Outcomes

Primary Outcome Measures

Feasibility of LOFT therapy in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy
Analysis of the modified intent-to-treat population defined as patients with at least 1 post-baseline measurement as well as eligible patients who decline participation, reason for refusal, and number of enrolled patients who do not complete all LOFT training sessions

Secondary Outcome Measures

Safety of LOFT intervention in this population patient reported adverse events
Assessed by patient reported adverse events
Heart rate
Power per body weight (muscle power)
Endurance
Assessed by patient self-report
Daily activity
Measured by Physical Activity Report questionnaire
Fatigue
Measured by BFI questionnaire
Quality of life
Measured by FACT-B questionnaire
Biochemical parameters of chronic inflammation
Blood samples
Biochemical parameters of metabolism and insulin homeostasis
Blood samples
Anabolic hormone secretion
Blood samples
Biochemical parameters of bone turnover
Blood samples

Full Information

First Posted
June 2, 2015
Last Updated
August 9, 2018
Sponsor
Kathy Miller
search

1. Study Identification

Unique Protocol Identification Number
NCT02491957
Brief Title
Impact of LOFT Therapy™ on Breast Cancer Survivors
Official Title
Impact of LOFT Therapy™ on Breast Cancer Survivors: A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
July 28, 2015 (Actual)
Primary Completion Date
March 29, 2018 (Actual)
Study Completion Date
March 29, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Kathy Miller

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and feasibility of LOFT Therapy in breast cancer survivors. In a previous study, the investigators found that many patients are more debilitated at diagnosis than previously recognized. Both chemotherapy and anti-estrogen therapy have a large effect. Within 6 months patients replace muscle with fat leading to a significant reduction in muscle power and endurance. Our data suggests that common exercise recommendations for at least 150 minutes of exercise a week would be far beyond many of our patients' physical ability after therapy, leading to the soreness, injury, frustration, and early discontinuation (or failure to initiate an exercise program in the first place). The degree of muscle loss seen in our patients is similar to that documented in US astronauts after long-term space flight. Our collaborator Dr. Yvonne Cagle, retired USAF flight surgeon, noted that the cosmonauts were in better shape (had less muscle atrophy) than the astronauts. This difference was more than could be explained by the rigorous Russian exercise program. The only key distinction was the compressive, "penguin suits" used by the Russians. This observation lead Dr. Cagle to develop a technique called low intensity, off loaded-compressive therapy (LOFT) to replicate the impact of the Russian penguin suits for patients who were debilitated, whether by space flight or by chronic conditions such as arthritis, Parkinson's disease, and multiple sclerosis. The LOFT method does not require excessive exertion or strain on the joints. In field observations, LOFT therapy improved muscle strength, muscle mass, endurance, sleep quality, and fatigue. This pilot study is the first to evaluate the safety, feasibility, and biologic impact of LOFT on breast cancer survivors.
Detailed Description
Objectives This pilot trial will provide feedback on the feasibility and impact of LOFT in breast cancer survivors. The investigators will also explore the relationship of the LOFT intervention to changes in insulin resistance, growth hormone levels, body mass index, patient reported physical activity, fatigue, and overall quality of life. Primary Objective Evaluate the safety and feasibility of LOFT training in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy. Secondary Objectives Estimate the effect size of LOFT training on muscle power, endurance, daily activity, fatigue, and quality of life. Estimate the effect of short-term LOFT training on biochemical parameters of inflammation, metabolism, anabolic hormone secretion, and bone turnover. LOFT Therapy™ Summary LOFT Therapy™ is a form of exercise that requires less energy for movement. LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort. The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement. Patients will undergo an intake and outtake assessment with each session to collect subjective data and patient feedback. Two compression sessions will be conducted for 4 weeks, for a total of 8 sessions. This study will enroll 15 patients. A 20% dropout rate for this group was taken into consideration so the investigators assume analysis will be done on at least 12 patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasms
Keywords
Energy Expenditure, Physical Endurance, Muscle Stength, Metabolism

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LOFT Therapy
Arm Type
Experimental
Arm Description
LOFT therapy twice weekly for 4 weeks
Intervention Type
Other
Intervention Name(s)
LOFT Therapy
Intervention Description
LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort. The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement.
Primary Outcome Measure Information:
Title
Feasibility of LOFT therapy in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy
Description
Analysis of the modified intent-to-treat population defined as patients with at least 1 post-baseline measurement as well as eligible patients who decline participation, reason for refusal, and number of enrolled patients who do not complete all LOFT training sessions
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Secondary Outcome Measure Information:
Title
Safety of LOFT intervention in this population patient reported adverse events
Description
Assessed by patient reported adverse events
Time Frame
Assessed at each session and throughout the intervention
Title
Heart rate
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Power per body weight (muscle power)
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Endurance
Description
Assessed by patient self-report
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Daily activity
Description
Measured by Physical Activity Report questionnaire
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Fatigue
Description
Measured by BFI questionnaire
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Quality of life
Description
Measured by FACT-B questionnaire
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Biochemical parameters of chronic inflammation
Description
Blood samples
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Biochemical parameters of metabolism and insulin homeostasis
Description
Blood samples
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Anabolic hormone secretion
Description
Blood samples
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Title
Biochemical parameters of bone turnover
Description
Blood samples
Time Frame
Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with stage 0-III breast cancer within the past 3 years Must have completed local therapy for their breast cancer Must have received systemic therapy for their breast cancer (anti-estrogen and/or chemotherapy) Chemotherapy must be complete prior to entry Anti-estrogen therapy may be ongoing Ambulatory without assistive devices No orthopedic restrictions or neurologic deficits that would limit ability to complete the Power Protocol (based on the opinion of the investigator) No requirement for supplemental O2 No unstable angina, regular use of nitroglycerin for exertional angina, or MI within the last 12 months No local or distant recurrence of their breast cancer No active lymphedema No history of hemorrhagic stroke No Heparin or Coumadin Use No symptomatic peripheral vascular obstructions No active gallbladder disease No active kidney stones No active gout No active diverticulitis No pituitary diseases or growth Able to provide written informed consent and authorization for release of health information Able to commit to LOFT training 2 times/week for 4 weeks Exclusion Criteria: Inability to meet one of the inclusion criteria above.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathy Miller, MD
Organizational Affiliation
Indiana University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Indiana University Health Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Indiana University Melvin and Bren Simon Cancer Center
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Impact of LOFT Therapy™ on Breast Cancer Survivors

We'll reach out to this number within 24 hrs